doi:10.3969/j.issn.1673-8640.2020.05.014

Abstract

CLC Number:

R446.1

Figures/Tables 4

References 12

[1]	范铮,沈丽萍,姚建华. 小儿疱疹性咽炎的病原学研究[J]. 浙江临床医学,2018,10(5):600-601.
[2]	EL HOUMAMI N,MINODIER P,DUBOURG G,et al.An outbreak of Kingella kingae infections associated with hand,foot and mouth disease/herpangina virus outbreak in Marseille,France,2013[J]. Pediatr Infect Dis J,2015,34(3):246-250.
[3]	CHEN Z,LI R,XIE Z,et al.IL-6,IL-10 and IL-13 are associated with pathogenesis in children with enterovirus 71 infection[J]. Int J Clin Exp Med,2014,7(9):2718-2723.
[4]	KURTIPEK E,BEKCI T T,KESLI R,et al.The role of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in exacerbation of chronic obstructive pulmonary disease[J]. J Pak Med Assoc,2015,65(12):1283-1287.
[5]	KAYRAK M,ERDOAN H I,SOLAK Y,et al.Prognostic value of neutrophil to lymphocyte ratio in patients with acute pulmonary embolism:a retrospective study[J]. Heart Lung Circ,2014,23(1):56-62.
[6]	夏蝉,余坚,金龙腾,等. 疱疹性口炎与疱疹性咽峡炎的病原学检测[J]. 中华全科医学,2016,14(10):1719-1722.
[7]	何亚萍,杜潘艳,郑建霞. 疱疹性咽峡炎患儿体内3种相关病毒检测及临床意义[J]. 中国热带医学,2016,16(1):90-92.
[8]	LIU H,ZHANG H,WAN G,et al.Neutrophil-lymphocyte ratio:a novel predictor for short-term prognosis in acute-on-chronic hepatitis B liver failure[J]. J Viral Hepat,2014,21(7):499-507.
[9]	ZAHOREC R.Ratio of neutrophil to lymphocyte counts-rapid and simple parameter of systemic inflammation and stress in critically ill[J]. Bratisl Lek Listy,2001,102(1):5-14.
[10]	PIROZZLO G,GISBERTZ S S,CASTORO C,et al.Neutrophil-to-lymphocyte ratio as prognostic marker in esophageal cancer:a systematic review and meta-analysis[J]. J Thorac Dis,2019 ,11(7):3136-3145.
[11]	WANG Z,GONG Q,GUO C,et al.Neutrophil-to-lymphocyte ratio predicts hematoma growth in intracerebral hemorrhage[J]. J Int Med Res,2019,47(7):2970-2975.
[12]	FARZANEH F,FAGHIH N,HOSSEINI M S,et al.Evaluation of neutrophil-lymphocyte ratio as a prognostic factor in cervical intraepithelial neoplasia recurrence[J]. Asian Pac J Cancer Prev,2019,20(8):2365-2372.

组别	例数	CRP/（mg/L）	WBC计数/（×10⁹/L）	NEUT%/%	LYMPH%/%	NLR
实验组	67
治疗前		27.87（30.40）	14.60±5.61	63.9±12.9	26.1±11.6	3.22±2.07
治疗后		3.63（4.97）	6.86±1.76	28.0±11.6	61.0±11.2	0.42（0.25）
对照组	44	0.86（1.74）	7.20±1.46	32.2±9.0	58.5±9.4	0.60±0.32

组别	例数	CRP/（mg/L）	WBC计数/（×10⁹/L）	NEUT%/%	LYMPH%/%	NLR
实验组	67
治疗前		27.87（30.40）	14.60±5.61	63.9±12.9	26.1±11.6	3.22±2.07
治疗后		3.63（4.97）	6.86±1.76	28.0±11.6	61.0±11.2	0.42（0.25）
对照组	44	0.86（1.74）	7.20±1.46	32.2±9.0	58.5±9.4	0.60±0.32

项目	阳性例数	阳性率/%
RSV	0	0.00
ADV	0	0.00
INFA	2	2.99
INFB	10	14.93
PIV	0	0.00
CP	1	1.49
MP	27	40.30
LP	0	0.00

项目	阳性例数	阳性率/%
RSV	0	0.00
ADV	0	0.00
INFA	2	2.99
INFB	10	14.93
PIV	0	0.00
CP	1	1.49
MP	27	40.30
LP	0	0.00

组别	治疗前
组别	CRP/（mg/L）	WBC计数/（×10⁹/L）	NEUT%/%	LYMPH%/%	NLR
MP阳性组	27.40（26.56）	16.19±5.91	70.1±10.9^*	20.4±8.8^*	4.44±2.67^*
MP阴性组	27.04（39.80）	13.62±5.20	59.8±12.9	29.7±12.1	2.55±1.53
组别	治疗后
组别	CRP/（mg/L）	WBC计数/（×10⁹/L）	NEUT%/%	LYMPH%/%	NLR
MP阳性组	3.49（3.27）	6.54±1.59	28.0±10.7	60.6±9.7	0.42（0.20）
MP阴性组	3.71（5.21）	7.1±1.81	28.1±12.4	61.0±12.2	0.42（0.29）

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 4

References 12

Related Articles 15

Recommended Articles

Metrics

[1]	FAN Lieying. Research status and application prospects of biomarkers for membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1111-1114.
[2]	SUN Lincheng, LI Jianfeng, CHENG Weili, JI Panyun. Roles of anti-PLA2R IgG4 antibody and PLA2R IgG4/IgG ratio in primary membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1115-1120.
[3]	LIU Qingyang, YUAN Jianming, XIA Jinjun, JIANG Fengying, WANG Qiubo, WANG Xiaoming. CXCL9 as a potential diagnostic marker of rheumatoid arthritis based on GEO database and experimental verification [J]. Laboratory Medicine, 2023, 38(12): 1121-1129.
[4]	YANG Xiao, LI Enling, WU Lixia, DAI Yingxin, WANG Zhiqing, HUANG Hao, ZHENG Bing. Influence of cytoplasmic antinuclear antibody on indirect immunofluorescence assay based antineutrophil cytoplasmic antibody determination [J]. Laboratory Medicine, 2023, 38(12): 1135-1140.
[5]	XIANG Jin, LIU Aiping, HU Yao, WU Zhiyuan, CAO Guojun, GUAN Ming. ANA profiles in COVID-19 patients and influence of serum heat-inactivation on ANA determination [J]. Laboratory Medicine, 2023, 38(12): 1141-1146.
[6]	CHENG Yu, XU Zhen, LU Liu, DING Menglei, YU Shanshan, ZONG Ming, FAN Lieying. Expression and risk factors of anti-ACE-2 antibody in serum of patients with COVID-19 [J]. Laboratory Medicine, 2023, 38(12): 1147-1152.
[7]	. [J]. Laboratory Medicine, 2023, 38(12): 1153-1156.
[8]	. [J]. Laboratory Medicine, 2023, 38(12): 1157-1159.
[9]	WANG Hongling, LIU Mengna, BAI Ping, LIAO Huanjin. Risk factors of relapse following allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia [J]. Laboratory Medicine, 2023, 38(12): 1160-1166.
[10]	YANG Xilan, WANG Jinyu, LIU Shuyu, ZHAN Yiyang, LIU Jing, JIA Jian. Correlation between hyperlipidemia and endothelial microparticles in elderly patients from Gulou Community in Nanjing [J]. Laboratory Medicine, 2023, 38(12): 1167-1172.
[11]	DAI Fangfang, LU Xinxin, YU Yanhua, CHEN Ming, SUN Guizhen. Analysis of Mycobacterium infection in HIV/AIDS patients [J]. Laboratory Medicine, 2023, 38(12): 1173-1176.
[12]	GU Yu, LIANG Xiaoyan, MA Shenghui, TONG Na, CHENG Mingyan, YAN Zejun. Expression and near-term prognostic predictive value of plasma biomarkers in chronic kidney disease patients with thromboembolism [J]. Laboratory Medicine, 2023, 38(12): 1177-1182.
[13]	. [J]. Laboratory Medicine, 2023, 38(12): 1183-1185.
[14]	. [J]. Laboratory Medicine, 2023, 38(12): 1186-1190.
[15]	. [J]. Laboratory Medicine, 2023, 38(12): 1191-1194.